Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00760344 · ClinicalTrials.gov registry record · Phase 2

Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus

A Phase 2 study of Diabetes Mellitus, sponsored by Takeda.

Completed
Registry status
Phase 2
Development phase
386
Enrollment target
20
Study locations

NCT00760344: Completed Phase 2 study of Diabetes Mellitus, sponsored by Takeda.

NCT00760344 is a Phase 2 study of Diabetes Mellitus that has completed, run by Takeda. The registered enrollment target is 386 participants, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (79% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00760344, a Phase 2 study of Diabetes Mellitus, has completed, sponsored by Takeda.

COMPLETED
Registry status
Phase 2
Development phase
386 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.

Conditions Studied

Diabetes Mellitus

Interventions

  • DRUG Placebo
  • DRUG SYR-472

Study Locations (20)

California

  • - Carmichael
  • - Chino
  • - Long Beach
  • - Los Angeles
  • - Los Gatos
  • - Orange
  • - Pico Rivera
  • - Rolling Hills Estates
  • - Roseville
  • - Rowland Heights
  • - Sacramento

Alabama

  • - Birmingham
  • - Mobile
  • - Montgomery

Arizona

  • - Phoenix
  • - Tempe
  • - Tucson

Arkansas

  • - Anderson
  • - Little Rock
  • - Pine Bluff

Trial Details

FieldValue
Enrollment Target 386 participants
Start Date 2007-03
Est. Completion 2008-03
Phase Phase 2
Takeda

408 total trials

What the finished NCT00760344 record still lists

NCT00760344 is an interventional study that assigns participants to a tested intervention. The registered 386 participants enrollment target is mid-sized for trials with a published cap, below the 1,866-participant average among 208 other Diabetes Mellitus trials with a reported enrollment target (79% lower).

The record links to 1 condition, with Diabetes Mellitus appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00760344 names 20 study sites across 4 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT00760344 about?

NCT00760344 is a clinical study titled "Efficacy and Safety of SYR-472 in Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to determine the efficacy and safety of SYR-472, once daily (QD), in subjects with type 2 diabetes mellitus who have not achieved glycemic control with diet and exercise, or by taking metformin.

What is the current status of trial NCT00760344?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 386 participants. The study started on 2007-03. Estimated completion is 2008-03.

What conditions does trial NCT00760344 study?

This clinical trial studies the following conditions: Diabetes Mellitus.

What interventions are being tested in trial NCT00760344?

The interventions under investigation include: Placebo (DRUG), SYR-472 (DRUG).

Who is sponsoring clinical trial NCT00760344?

This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00760344 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diabetes Mellitus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00760344's enrollment target sits among peer trials

386 56th of 208 higher than 153 of 208 other Diabetes Mellitus trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05645107 · 386 participants · Phase 3

    A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  • NCT05896189 · 386 participants · NA

    Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors

  • NCT06686121 · 386 participants · Phase 3

    Improving Mobility After Revascularization in Peripheral Artery Disease

  • NCT07424547 · 386 participants · Phase 1

    Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00760344, the US trial registry maintained by the National Library of Medicine. NCT00760344 (mid enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.